These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6628700)

  • 1. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer.
    Weber WW; Hein DW; Litwin A; Lower GM
    Fed Proc; 1983 Nov; 42(14):3086-97. PubMed ID: 6628700
    [No Abstract]   [Full Text] [Related]  

  • 2. Isoniazid acetylator phenotype.
    Raghupati Sarma G
    Indian Pediatr; 1989 Feb; 26(2):197-8. PubMed ID: 2753546
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
    Wolf H; Lower GM; Bryan GT
    Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator status, drug metabolism and disease.
    Pande JN; Pande A; Singh SP
    Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overrepresentation of the slow acetylator phenotype in painters suffering from urinary bladder cancer.
    Golka K; Kempkes M; Flieger A; Blaszkewicz M; Bolt HM
    Med Lav; 1997; 88(5):425-6. PubMed ID: 9489306
    [No Abstract]   [Full Text] [Related]  

  • 6. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of Syrian hamster lines congenic at the polymorphic acetyltransferase locus (NAT2): acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens.
    Hein DW; Doll MA; Rustan TD; Gray K; Ferguson RJ; Feng Y
    Toxicol Appl Pharmacol; 1994 Jan; 124(1):16-24. PubMed ID: 8291057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
    Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
    Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis.
    Dewan A; Chattopadhyay P; Kulkarni PK
    Indian J Cancer; 1995 Mar; 32(1):15-9. PubMed ID: 7558106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and its clinical implications: N-acetylation polymorphism.
    Horai Y; Ishizaki T
    Ration Drug Ther; 1987 Oct; 21(10):1-7. PubMed ID: 3326026
    [No Abstract]   [Full Text] [Related]  

  • 12. [The mechanism of in vivo arylamine acetyltransferase activation].
    Ksenzenko SM; Ksenzenko MIu
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1990; (1):19-24. PubMed ID: 2346768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
    Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic regulation of N-acetyltransferase in target organs of arylamine tumors: homologous expression in human and hamster bladder and colon.
    Hein DW
    Proc West Pharmacol Soc; 1991; 34():55-60. PubMed ID: 1788341
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinetics of acetyl coenzyme A:arylamine N-acetyltransferase from rapid and slow acetylator frog tissues.
    Ho CC; Lin TH; Lai YS; Chung JG; Levy GN; Weber WW
    Drug Metab Dispos; 1996 Feb; 24(2):137-41. PubMed ID: 8742223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetyltransferase activity is involved in paclitaxel-induced N-acetylation of 2-aminofluorene in human bladder cancer cells (T24).
    Yang CC; Yang JH; Lu HF; Chen SY; Lin SY; Chung JG
    Anticancer Res; 2004; 24(3a):1501-6. PubMed ID: 15274316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.
    Rothman N; Garcia-Closas M; Hein DW
    Int J Epidemiol; 2007 Feb; 36(1):23-8. PubMed ID: 17510073
    [No Abstract]   [Full Text] [Related]  

  • 18. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
    Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
    Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activity of acetylation processes in patients with disseminated sclerosis].
    Selezenev NG
    Lab Delo; 1984; (12):754-5. PubMed ID: 6084114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.